Abstract
Solubility is an essential factor for drug effectiveness, independent of the route of administration. Poorly soluble drugs are often a challenging task for formulators in the industry. Conventional approaches for enhancement of solubility have limited applicability, especially when the drugs are poorly soluble simultaneously in aqueous and in non-aqueous media. Nanosuspension technology can be used to improve the stability as well as the bioavailability of poorly soluble drugs. The problem is even more complex for drugs like itraconazole, simvastatin, and carbamazepine which are poorly soluble in both aqueous and nonaqueous media, belonging to BCS class II as classified by biopharmaceutical classification system. Formulation as nanosuspension is an attractive and promising alternative to solve these problems. Nanosuspension consists of the pure poorly water-soluble drug without any matrix material suspended in dispersion. Preparation of nanosuspension is simple and applicable to all drugs which are water insoluble. A nanosuspension not only solves the problems of poor solubility and bioavailability, but also alters the pharmacokinetics of drug and thus improves drug safety and efficacy. This review article describes the preparation methods, characterization, and applications of the nanosuspension.
References
S. Vermaa, Y. Lan , R. Gokhale , DJ. Burgessa. Quality by design approach to understand the process of nanosuspension preparation. Int J Pharm 377 (2009) 185– 98. [PubMed]
P. Nagaraj, K. Krishnachaithanya , VD. Srinivas , SV. Padma . Nanosuspensions: A promising drug delivery systems. Int J Pharm Sci Nano 2 ( 2010) 679–84.
ER. Barre. Nanosuspensions in drug delivery. Nat Rev 3 (2004) 785–96. [PubMed]
RH. Muller , S. Gohla, A. Dingler ,T. Schneppe ,D. Wise . Handbook of pharmaceutical controlled release technology. New York: Marcel Dekker (2000). Large-scale production of solid-lipid nanobparticles (SLN) and nanosuspension (Dissocubes) 359–375.
Nanosuspension systems, Hamamatsu Nano technology. [cited 2011 Mar 5]. Available from: http://www.hamanano.com/e/products/c3/c3_1 /
.GG. Liversidge , KC. Cundy . Particle size reduction for improvement of oral bioavailability of hydrophobic drugs: Absolute oral bioavailability of nanocrystalline danazol in beagle dogs. Int J Pharm.125 (1995) 91–97.
. H.Sucker . Hydrosole, eine Alternative fόr die parenterale Anwendung von schwer was serloslichen Wirkstoffen. In: RH. Muller, GE. Hildebrand, editors. Pharmazeutische Technologie; Modern Arzneiformen. 2 nd ed. Stuttgart: WVG; (1998).
.RH. Muller ,K. Peters ,R. Becker,B. Kruss. Nanosuspension for IV administration of poorly soluble drugs-Stability during sterilization and long term storage. Proc Int Symp Control Rel Bioact Mater 22 (1995) 574-5.
.K.P.R. Chowdary and B.L.R Madhavi ., Novel drug delivery technologies for insoluble drugs. Ind.Drugs 42 (2005) 557-563.
. M. Corneli , Keck, H. Raine . Muller. Drug nanocrystals of poorly soluble drugs produced by high-pressure homogenisation. Eur. J. Pharm.Biopharm 62 (2006) 3–16.
. V.B. Patravale and A. Abhijit. Nanosuspensions: a promising drug delivery strategy. J.Pharm.Pharcol 56 (2004) 827-840.
V.B.Patravale, Abhijit A.Date and R.M.Kulkarni. Nanosuspensions: a promising drug delivery strategy. J.Pharm.Pharcol 56 (2004) 827-840.
R.H.Muller, B.H.L.Bohm and .J.Grau. Nanosuspensions : a formulation approach for Poorly soluble and poorly bioavailable drugs. In D.Wise (Ed) Handbook of pharmaceutical controlled release technology (2000) 345- 357.
. M. Cornelia . Keck, H. Rainer . Muller. Drug nanocrystals of poorly soluble drugs produced by high-pressure homogenisation. Eur. J. Pharm.Biopharm 62 (2006) 3–16.
. K.P. Krause, O. Kayser, K. Mader, R. Gust, R.H. Muller. Heavy metal intamination of nanosuspensions produced by high-pressure homogenisation. Int J. Pharm 196 (2000) 169– 172.
. K.P.Krause, R.H.Muller. Production and characterization of highly concentrated nanosuspensions by high pressure homogenisation. Int.J.Pharm 214 (2001) 21-24 .
. Jan Moschwitzer, Georgr Achleitner, Herberk Pomper, Rainer H.Muller. Development of an intraveneously injectable chemically stable aqueous omeprazole formulation using nanosuspension. Eur. J. Pharm. Biophar 58 (2004) 615- 619.
. R. Bodmeier, J.M. McGinity, Solvent selection in the preparation of poly(DLlactide) microspheres prepared by solvent evaporation method. Int. J.Pharm., 43 (1998), 179-186.
. VB Patravale, AA Date and RM Kulkarni. Nanosuspension: a promising drug delivery strategy. J. Pharm. Pharmacol 56 (2004) 827- 840.
. M Trotta, M Gallarate, ME Carlotti and S Morel. Preparation of griseofulvin nanoparticles from water- dilutable microemulsions. Int. J. Pharm 254 (2003) 235-242.
. R. Dearns . Atovaquone pharmaceutical compositions. US Patent US 6018080, 2000.
.TJ. Young , S. Mawson ,KP. Johnston , IB. Henriska ,GW Pace, AK. Mishra . Rapid expansion from supercritical to aqueous solution to produce submicron suspension of water insoluble drugs. Biotechnol Prog 16 (2000) 402-407.
. V. B. Patravale, A. Abhijit . Date and R. M. Kulkarni , Nanosuspensions: a promising drug delivery strategy, JPP 56 (2004) 827–840
.T. Shah, D. Patel, J. Hirani , AF Amin . Nanosuspensions as a drug delivery systems-A comprehensice review. Drug Del Tech 7 (2007) 42-53.
.TJ. Young, S. Mawson , KP Johnston , IB. Henriska ,GW. Pace ,AK. Mishra . Rapid expansion from supercritical to aqueous solution to produce submicron suspension of water insoluble drugs. Biotechnol Prog16 ( 2000) 402–407. [PubMed]
AN. Kumar, M. Deecaraman ,C Rani . Nanosuspension technology and its applications in drug delivery. Asian J Pharma 3 (2009) 168–173.
Y. Chen , J. Liu ,X. Yang , X.Zhao . Oleanolic acid nanosuspensions: Preparation, in-vitro characterization and enhanced hepatoprotective effect. J Pharm Pharmacol.57 (2005) 259–64. [PubMed]
JP Higgins . Spectroscopic approach for on-line monitoring of particle size during the processing of pharmaceutical nanoparticles. Anal Chem75 (2003) 1777– 1785. [PubMed]
P. Setler . London: IIR Limited Drug delivery system; (1999). Identifying new oral technologies to meet your drug delivery needs for the delivery of peptides and proteins and poorly soluble molecules.
RH. Muller , C. Jacobs . Production and characterization of a budesonide nanosuspension for pulmonary administration. Pharm Res.19 (2002) 189–194. [PubMed] 31)JZ Yang ,AL Young ,PC Chiang ,A Thurston ,DK Pretzer . Fluticasone and budesonide nanosuspensions for pulmonary delivery: Preparation, characterization, and pharmacokinetic studies. J Pharm Sci 97 (2008) 4869–4878. [PubMed]
YC Liang ,JG Binner . Effect of triblock copolymer non- ionic surfactants on the rheology of 3 mol% yttria stabilised zirconia nanosuspensions. Ceram Int. 34 (2008) 2937
RH.Muller ,MJ Grau . Increase of dissolution rate and solubility of poorly water soluble drugs as nanosuspension.Proceedings. World Meeting APGI/APV, Paris 2 (1998) 62–624.
L. Bond ,S. Allen , MC Davies ,CJ Roberts ,AP Shivji , SJ Tendler et al. Differential scanning calorimetry and scanning thermal microscopy analysis of pharmaceutical materials. Int J Pharm 243 (2002) 71–82. [PubMed]
R.H.Muller, B.H.L.Bohm and .J.Grau. Nanosuspensions : a formulation approach for poorly soluble and poorly bioavailable drugs. In D.Wise (Ed.) Handbook of pharmaceutical controlled release technology (2000) 345- 357.
R.H. Muller, C.Jacobs, O. Kayser. Nanosuspensions as particulate drug formulations in therapy Rationale for development and what we can expect for the future. Ad.Drug Del.Rev 47 (2001) 3-19.
B.W .Muller, R.H.Muller. Particle size analysis of latex suspensions and microemulsions by Photon Correlation Specroscopy.J.Pharm.Sci. 73 (1984) 915-918.
Montasser, H. Fessi, A.W. Coleman. Atomic force microscopy imaging of novel type of polymeric colloidal nanostructures. Eur. J.Pharm.Biopharm 54 (2002) 281–284.
Laura Bond, Stephanie Allen , C. Martyn . Davies, J.Clive . Roberts, P. Arif .. Differential scanning calorimetry and scanning thermal microscopy analysis of pharmaceutical materials.Int.J.Pharm 243 (2002) 71–82.
N. Scholer, K.Krause, O.Kayser, R.H Muller, K. Borner, H. Hahn, O. Liesenfeld, Atovaquone nanosuspensions show excellent therapeutic effect in a new murine model of reactivated toxoplasmosis. Antimicrob.Agents Chemother 45 (2001) 1771 –1779.
K.Peters ,S. Leitzke , JE Diederichs , K. Borner ,H. Hahn , RH. Mόller et al Preparation of a clofazimine nanosuspensions for intravenous use and evaluation of its therapeutic efficacy in murine mycobacterium avium infection. J Antimicrob Chemother 45 (2000) 77-83.
BH. Boedeker , EW Lojeski ,MD Kline , DH. Haynes .Ultra-long duration local anesthesia produced by injection of lecithin-coated tetracaine microcrystals. J Clin Pharmacol 34 (1994) 699-702.
L. Jia , H. Wong , C.Cerna ,SD. Weitman . Effect of nanonization on absorption of 301029: Ex vivo and in vivo pharmacokinetic correlations determined by liquid chromatography/mass spectrometry. Pharm Res 19 (2002) 1091-6.
EM. Liversidge. Formulation and antitumor activity evaluation of nanocrystalline suspensions of poorly soluble anticancer drugs. Pharm Res 13 (1996) 272- 278.
R. Pignatello ,N. Ricupero ,C. Bucolo ,F. Maugeri ,A. Maltese ,G. Puglisi . Preparation and characterization of Eudragit retard nanosuspensions for the ocular delivery of cloricromene. AAPS Pharmscitech 7 (2006) E27.
P. Setler . Identifying new oral technologies to meet your drug delivery needs for the delivery of peptides and proteins and poorly soluble molecules. IIR Limited, Drug delivery systems London: (1999).
GC. Liversidge. Paper presented at the 23 rd International symposium of the Controlled Release Bioactive Materials Society. Workshop on Particulate Drug Delivery Systems;(1996). 46.
O.Kayser , C. Olbrich , V. Yardley , AP Kiderten , SL. Croft . Formulation of amphotericin-B as nanosuspension for oral administration. Int J Pharm 254 (2003) 73-5.
Y. Chen, J. Liu, X. Yang, X. Zhao. Oleanolic acid nanosuspensions: preparation, in-vitro characterization and enhanced hepatoprotective effect. J. Pharm. Pharmacol., 57 (2005) 259-264.
G. Ponchel , MJ Montisci ,A. Dembri ,C. Durrer ,D. Duchκne. . Mucoadhesion of colloidal particulate systems in the gastrointestinal tract. Eur J Pharm Biopharm 44 (1997) 25 31.
O. Kayser . A new approach for targeting to Cryptosporidium parvum using mucoadhesive nanosuspensions: r0 esearch and applications. Int J Pharm 214 (2001) 83-5.
Khan S., Tiwari T., Tyagi S., Mithun B, Joshi A., Dubey B., “Preformulation studies and preperation of dithranol loaded solid lipid nanoparticles”, Int. J. Res. Dev. Pharm. L. Sci., 2012, 1(4), pp. 183-188.
How to cite this article:
Soumya M., Gupta S., A review on “Solubility enhancement of poorly water soluble drug by using nano-suspension technology”, Int. J. Res. Dev. Pharm. L. Sci., 2013, 2(6), pp.642-649.
This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.
Copyright (c) 2020 Array